Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Since the mortality rates for patients with advanced ovarian carinoma are high, the most
likely way to improve progression free and overall survival is with maximal "upfront" therapy
(Morrow & Curtin, 1998). Currently, no triplet regimen has demonstrated compelling
superiority. Therefore, the combination of Paclitaxel, Carboplatin, and Vorinostat is
intriguing because of their potential synergy, distinct mechanisms of action, and
non-overlapping toxicity.